Granules India

Granules India is a pharmaceutical company headquartered in India that focuses on the development, manufacture, and supply of active pharmaceutical ingredients (APIs) and finished dosage forms. The company serves both domestic and international markets, providing products to generic drug manufacturers, contract research organizations, and healthcare providers across multiple therapeutic areas. Its product portfolio includes intermediates, bulk drugs, and formulations that are used in the production of antibiotics, cardiovascular agents, anti‑infective medicines, and central nervous system drugs. Granules India operates several manufacturing facilities that are designed to meet stringent quality standards such as WHO‑GMP, USFDA, EU‑GMP, and TGA requirements. These facilities enable the company to export to regulated markets in North America, Europe, Australia, and emerging economies in Asia and Africa. In addition to manufacturing, Granules India invests in process research and analytical development to improve yields, reduce environmental impact, and support the launch of new generic molecules. The firm also engages in contract manufacturing services, offering customized synthesis and formulation solutions to partner companies seeking outsourced production capacity. Continuous investment in technology upgradation and staff training underpins its ability to maintain compliance with evolving global regulatory expectations.

While specific employee count or revenue figures are not provided in the source material, Granules India is recognized as a mid‑size player in the Indian pharmaceutical sector with a notable presence in the API segment. The company distinguishes itself through an integrated business model that combines API synthesis with formulation capabilities, allowing it to offer end‑to‑end solutions from raw material to finished drug product. Regulatory compliance is a core focus, and Granules India has a track record of successful inspections by agencies such as the USFDA, EMA, MHRA, and TGA, which supports its eligibility to supply regulated markets. The organization adheres to internationally recognized quality management systems to support consistent product quality and operational reliability. In May 2023 Granules India reported an information security incident that led to the isolation of impacted IT assets, prompting containment and remediation actions in line with industry best practices and internal incident‑response protocols. The incident was communicated to stakeholders through a regulatory filing, and the company stated that appropriate measures were taken to restore normal operations without compromising product quality or supply continuity. Granules India is publicly listed on Indian stock exchanges, with its shares traded under the ticker GRANULES on the National Stock Exchange (NSE) and under the code 532482 on the Bombay Stock Exchange (BSE). This public listing reflects a corporate structure that includes promoter holdings, institutional investors, and public shareholders, providing the company with access to capital for expansion and strategic initiatives.